Hydroxy Itraconazole (R63373) is a triazole compound with antifungal activity for the study of malignant tumors.

Hydroxy Itraconazole is considered to have antifungal effects in vitro. It contains a triazole ring in its structure and is capable of inhibiting the CYP3A enzyme. [1]

Plasma concentrations of Hydroxy Itraconazole do not correlate well with ITZ doses, probably because the process of forming Hydroxy Itraconazole is saturated. Factors such as serum albumin and GFR affect the pharmacokinetics of ITZ and Hydroxy Itraconazole. When considering antifungal activity, it is important to look not only at plasma concentrations of ITZ, but also at plasma concentrations of Hydroxy Itraconazole. However, the pharmacokinetics of Hydroxy Itraconazole in immunocompromised patients receiving oral ITZ solutions are similar to those of ITZ. Therefore, since plasma concentrations of ITZ and Hydroxy Itraconazole are highly correlated, determining plasma concentrations of both should be sufficient from a clinical standpoint. [1]